ADPT (Adaptive Biotechnologies) Short Interest


ADPT Adaptive Biotechnologies Corp ADPT
73 GF Score
Price $19.34
GF Value $10.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ADPT vs GRAL, WGS, NEO: Short Interest Comparison

For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's Short Interest distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Short Interest falls into.


ADPT
73GF Score
Adaptive Biotechnologies Corp ADPT
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $19.34 is trading 92.2% above its estimated GF Value™ of $10.06. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Short Interest:
  • GF Value™: $10.06 vs. price of $19.34 (92.2% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
73GF Score

Get the complete analysis for ADPT

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.34
Price
$10.06
GF Value